Optimization of antitubercular compounds against a novel mycobacterium tuberculosis target, aspc - tuberculosis (TB) is once again the leading cause of death from infectious disease
Active Grant Awarded
- Award ID
- R01AI195815
- Recipient
-
Trudeau Institute Inc. UEI N6K7XKLGRJ61
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $921,320
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 16% complete
- Place of performance
- Saranac Lake, NY, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services' National Institutes of Health, through the National Institute of Allergy and Infectious Diseases, awarded Trudeau Institute Inc. $921,320 on January 28, 2026, under Assistance Listing 93.855, Allergy and Infectious Diseases Research. The grant (R01AI195815) funds optimization of TI-374, a molecule originally identified for cognitive impairment associated with schizophrenia that shows high potency against Mycobacterium tuberculosis, with the goal of progressing it into a lead compound. The work takes a ligand-based approach to expand structure-activity relationship analysis and improve potency against the M. tuberculosis alanine aminotransferase (ASPC) enzyme, which preliminary data identify as TI-374's novel target. Efficacy is measured through antibiotic susceptibility assays and on-target ASPC enzyme assays.
Obligated funding equals the $921,320 total. The period of performance runs from January 28, 2026 through the ultimate completion date of December 31, 2030. Place of performance is Saranac Lake, NY, USA. The assistance type is a grant. The source identifies no sub-recipients for this award.
Description
Current TB treatments are complex, lengthy and have undesirable side effects. As a result, cases of multi-drug resistant and extensively-drug resistant TB are on the rise. Compounding this problem of rising drug resistance is the notable lack of innovation in drug discovery; new antibiotics are often chemically similar, target the same few bacterial pathways (e.g. cell wall, nucleic acid and protein synthesis) for which mechanisms of resistance are well established, and are slow to come to market. Therefore, the discovery of chemically distinct therapeutics that act via novel mechanisms is necessary to overcome the emergence of resistant strains. In addition, drug repurposing represents an attractive option to mitigate cost, time and safety risk associated with antibiotic development. We have identified a molecule (TI-374) with high potency (0.1 ΜG/ML) against mycobacterium tuberculosis (MTB), originally identified to treat cognitive impairment associated with schizophrenia and psychiatric disorders. Preliminary data indicates that this molecule acts on a novel MTB target, the alanine aminotransferase aspc, which was observed to be essential in a transposon mutagenesis screen and we show to be important for bacterial survival in a murine model of MTB infection. TI-374 has drug-like and lead- like properties, a novel mechanism of action and a distinctive chemical structure, thereby addressing the major hurdles plaguing antibiotic drug development. We have proposed to optimize TI-374 against MTB and progress IT into a lead compound. Key ideas underlying our approach are as follows: (I) taking a ligand-based approach, we will expand structure-activity relationship (SAR) and optimize potency for efficacy against MTB aspc using antibiotic susceptibility assays as well as on-target aspc enzymatic assays and off-target enzymatic assays to counter screen against the original human target and a known human ortholog, (II) advancement of potent, on- target analogs to extensive in vitro adme and in vivo PK studies and (III) characterization of pharmacological and genetic inhibition of aspc in a murine chronic infection model. With completion of this proposal, we expect to identify 1-2 advanced leads, as well as validate aspc as a novel druggable target, enabling further studies for the treatment of MTB. We believe the proposal provides an innovative approach to develop new therapeutic avenues to treat MTB infections, which is an urgent unmet need.
Quick answers
Who received award R01AI195815?
R01AI195815 was awarded to Trudeau Institute Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on January 28, 2026.
How much is award R01AI195815 worth?
$921,320 has been obligated on R01AI195815.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award